Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

Bioinformatics based platform enabling precision medicine, nutrition and cosmetics through the discovery of biomarkers

Country of Origin: Greece
Reference Number: TOGR20190517001
Publication Date: 17 May 2019

Summary

A Greek SME has developed a platform enabling precision medicine, nutrition and cosmetics through the discovery of biomarkers, which focuses on analysis of complex life-science and biological data. This solution expedites prognosis and diagnosis process for certain diseases through the isolation of biomarkers, which are confidently related to the cause of the disease. The Greek SME is looking for partners to cooperate with under commercial, financial or research cooperation agreement.

Description

A Greek SME is a bioinformatics pioneer company in precision medicine, nutrition and cosmetics, which focuses on providing computational frameworks and tools for the analysis of complex life-science and biological data.

The most significant bottleneck of research in biotechnology, personalized medicine, pharma & personalized nutrition is the identification of accurate prognostic, diagnostic and therapeutic biomarkers which will enable the physicians to diagnose a forthcoming disease and treat it appropriately in a personalized manner before the disease affects the patient’s life or otherwise predict the impact of drugs and nutritional products at molecular level.

The company’s approach is unique and it is able to expedite prognosis and diagnosis process for certain diseases through the isolation of fewer, more relevant and prioritized integrated biomarkers, which are confidently related to the cause of the disease; contrary to current methods which only relate to its symptoms. The company proved able to reduce time and costs of extracting predictive biomarkers to 1/6 and 1/8 respectively.

The company’s suite of products consists of cloud-driven bioinformatics tools, able to integrate biological data from various sources and provide comprehensive results and meaningful knowledge (early stage biomarkers of high quality & biological systemic interpretation) using advanced big-data-oriented artificial intelligence methods and tools. The suite is tested by more than 400 users. Research and industry collaborative projects are also part of the process of getting the suite known.

Targeted end users in the health, nutrition and cosmetic industries are the R&D departments of bio-pharma, nutrition, cosmetics & applied research companies who need bioinformatics tools & services but also molecular biology and bioinformatics academics. In more detail, end users target groups are universities, biology labs, medical/biological devices companies, while pharmaceuticals, contract research organizations, medical practitioners, hospital labs, IT companies and bio-statisticians can either be end users target groups or strategic partners.

Partners sought are basically from the industry of pharmaceutics, nutrition and cosmetics that conduct molecular biology research for their product’s design and pre-clinical and clinical trials. The company is looking for partners to cooperate with under commercial, financial or research cooperation agreement.

Advantages and Innovations

The company’s patented technology offers unique inside path to an integrated end-to-end accurate biomarker discovery process, simultaneous integration of data from different sources and has demonstrated ability to locate significantly more common proteins in large scale proteomics datasets. The company’s solutions are based on biological networks modeling to integrate complex biological information in many layers (mutations, proteins, clinical variables, etc.) and advanced big data-oriented artificial intelligence methods.

The company owns the following computational frameworks:
Patented method for assigning functional annotation to all molecules and predicting physical protein-protein interactions.

Ribonucleic acid sequencing (RNA-seq) analysis pipeline that maximizes non-coding RNA discovery (patent pending).

Network based biomarker discovery pipeline able to locate the cause of diseases instead of their results (patent pending).

Deoxyribonucleic acid sequencing (DNA-seq) analysis pipeline that locates only disease related mutations and ranks them with severity score (patent pending).

Current bioinformatics products are either embedded to experimental instruments or standalone tools and platforms. Both categories of competitors provide limited functionalities for an overwhelming cost and require hardware equipment and expertise for installation and usage. Bioinformatics companies offering software applications rely mainly on statistical analysis.

The suite is able to expedite prognosis and diagnosis process for diseases as well as the prediction of the impact of certain drugs and nutrition products in health at the molecular level through the isolation of much fewer, more relevant integrative biomarkers related to the cause of the disease and not its symptoms-as current methods do. Using the suite, biology researchers can save time and money while reassuring high performance and robustness in their data analysis.

Stage Of Development

Already on the market

Stage Of Development Comment

The product is continuously evolving with new features and analytics/predictive capabilities. Current version on the market is tested by more than 400 biology researchers and bioinformaticians the last three years.

Requested partner

Commercial agreement with technical assistance: The company provides a cloud-driven suite of bioinformatics tools, able to integrate biological data from various sources and provide comprehensive results and meaningful knowledge to biology researchers. Potential partners are organisations conducting molecular biology related research such as pharmaceuticals companies.

Financial Agreement: The company has initiated, this year, a Seed funding round for the further development of the provision platform and the commercialization of its own experimental verified biomarkers. Company is looking for funds in the area of health and personalised medicine with connections to pharmaceuticals companies and clinical research organisations specialised in pre-clinical and clinical trials.

Research cooperation agreement: The company offers biological data analytics (bioinformatics) services towards the discovery of biomarkers. This R&D services can be utilised by R&D departments, research laboratories and applied research companies activated in the industry of pharmaceutics, nutrition and cosmetics.

Kooperationsanfrage stellen